New endocrine therapy for patients with scirrhous type gastric cancer using LH-RH analogue (Zoladex)

为了改善硬癌患者的预后，我们研究了LH-RH类似物（Zoladex）的内分泌治疗新方法。1.抑制癌细胞株的研究。结果发现，1 × 10 ~（-10）μ M的Zoladex与E_2合用，可抑制KATO-Ⅲ细胞株（雌激素受体阳性细胞）的增殖<-6><-7>。而1 × 10 ~（-10）μ M Zoladex与E_2对ER阴性细胞MKOI的增殖无抑制作用<-6><-7>。Zoladex对荷瘤裸鼠的Kato-III细胞有明显的抑制作用。在硬结型胃癌患者中，服用Zoladex后血清雌激素水平降低。然而，尚不清楚Zoladex是否能减少硬结型胃癌的大小。本研究结果提示，舒莱得对硬化型胃癌有一定的治疗作用。

In order to improving prognosis of scirrhous type gastric cancer patients, we studied new endocrine therapy using LH-RH analogue (Zoladex). 1. Studies on inhibition of cancer cell line. It was found that the proliferation of the KATO-III cell line (estrogenreceptor-positivecell) was inhibited by 1x10^<-6>-10^<-7>M Zoladex with E_2. On the other hand, the proliferation of MKOI (ER negative cell) was not inhibited by 1x10^<-6>-10^<-7>M Zoladex with E_2. In nude mouse bearing xenograft tumor, Kato-III cells were inhibited by Zoladex. In patients with scirrhous-type gastric cancer, the levels of serum estrogen decreased after administration of Zoladex. However, it was not clear that the size of scirrhous-type gastric cancer decreased by Zoladex. In the present study, it can be concluded that Zoladex might be useful for the treatment of scirrhous-type gastric cacer.